MarketResearchReports.biz has recently announced the addition of a market study “ Irritable Bowel Syndrome - Pipeline Review, H2 2016 ”, is a comparative analysis of the global market.
Irritable Bowel Syndrome - Pipeline Review, H2 2016
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome Pipeline Review, H2 2016, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape.
Inflammatory Bowel Diseases (IBD) is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. Signs and symptoms include abdominal cramps and pain, diarrhea that may be bloody, weight loss, loss of appetite and fever. The predisposing factors include age, family history, smoking and some pain killers. Treatment includes corticosteroids, immune suppressors, antibiotics and pain relievers.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 10, 6, 9 and 1 respectively.Irritable Bowel Syndrome.
Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table Of Content
Table of Contents 2
List of Tables 7
List of Figures 8
Global Markets Direct Report Coverage 9
Irritable Bowel Syndrome Overview 10
Therapeutics Development 11
Pipeline Products for Irritable Bowel Syndrome - Overview 11
Irritable Bowel Syndrome - Therapeutics under Development by Companies 12
Irritable Bowel Syndrome - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Irritable Bowel Syndrome - Products under Development by Companies 17
Irritable Bowel Syndrome - Companies Involved in Therapeutics Development 19
4D Pharma Plc 19
A. Menarini Industrie Farmaceutiche Riunite Srl 20
Alfa Wassermann S.p.A 21
Ardelyx, Inc. 22
Astellas Pharma Inc. 23
CJ HealthCare Corp. 24
Dong-A Socio Holdings Co. Ltd. 25
Enterome Bioscience SA 26
GlaxoSmithKline Plc 27
Innovative Med Concepts, LLC 28
Ironwood Pharmaceuticals, Inc. 29
Kissei Pharmaceutical Co., Ltd. 30
Lexicon Pharmaceuticals, Inc. 31
Napo Pharmaceuticals Inc 32
Ono Pharmaceutical Co., Ltd. 33
Pfizer Inc. 34
RaQualia Pharma Inc. 35
RedHill Biopharma Ltd. 36
SK Biopharmaceuticals Co., Ltd. 37
Sumitomo Dainippon Pharma Co Ltd 38
Synergy Pharmaceuticals, Inc. 39
Synthetic Biologics, Inc. 40
Vitality Biopharma Inc 41
Irritable Bowel Syndrome - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Combination Products 43
Assessment by Target 44
Assessment by Mechanism of Action 46
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53